 Clifford Greyson
Concepts (170)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ventricular Dysfunction, Right | 4 | 2010 | 217 | 0.780 |
Why?
| | Ventricular Function, Right | 3 | 2011 | 250 | 0.720 |
Why?
| | Calpain | 2 | 2012 | 53 | 0.680 |
Why?
| | Heart Failure | 5 | 2012 | 1945 | 0.630 |
Why?
| | Myocardial Contraction | 7 | 2013 | 313 | 0.580 |
Why?
| | Myocardial Reperfusion Injury | 5 | 2013 | 95 | 0.550 |
Why?
| | Hypertension, Pulmonary | 4 | 2012 | 1729 | 0.450 |
Why?
| | Swine | 20 | 2017 | 700 | 0.440 |
Why?
| | Pulmonary Heart Disease | 1 | 2012 | 6 | 0.420 |
Why?
| | Heart Ventricles | 7 | 2012 | 712 | 0.420 |
Why?
| | Hemodynamics | 11 | 2012 | 1012 | 0.410 |
Why?
| | Talin | 1 | 2012 | 7 | 0.400 |
Why?
| | Cardiotonic Agents | 4 | 2008 | 119 | 0.390 |
Why?
| | Pulmonary Circulation | 2 | 2012 | 407 | 0.380 |
Why?
| | Adenosine Triphosphate | 5 | 2017 | 430 | 0.350 |
Why?
| | Adenosine Diphosphate | 2 | 2008 | 81 | 0.320 |
Why?
| | Coronary Occlusion | 1 | 2008 | 18 | 0.310 |
Why?
| | Ventricular Fibrillation | 3 | 2017 | 51 | 0.310 |
Why?
| | Prodrugs | 1 | 2008 | 42 | 0.310 |
Why?
| | Intensive Care Units | 1 | 2012 | 617 | 0.300 |
Why?
| | Ventricular Function | 2 | 2008 | 57 | 0.300 |
Why?
| | Ventricular Pressure | 1 | 2007 | 38 | 0.290 |
Why?
| | Folic Acid | 1 | 2008 | 161 | 0.290 |
Why?
| | Heart | 6 | 2009 | 612 | 0.260 |
Why?
| | Myocardial Ischemia | 5 | 2017 | 235 | 0.260 |
Why?
| | Acute Disease | 4 | 2012 | 911 | 0.260 |
Why?
| | Metabolic Syndrome | 3 | 2013 | 321 | 0.230 |
Why?
| | Thiazolidinediones | 4 | 2012 | 142 | 0.220 |
Why?
| | PPAR gamma | 3 | 2012 | 182 | 0.200 |
Why?
| | Cardiac Output | 2 | 2012 | 143 | 0.180 |
Why?
| | Dipeptides | 2 | 2012 | 48 | 0.170 |
Why?
| | Animals | 24 | 2017 | 31710 | 0.170 |
Why?
| | Energy Metabolism | 5 | 2004 | 731 | 0.150 |
Why?
| | Swine, Miniature | 3 | 2013 | 71 | 0.150 |
Why?
| | Coronary Circulation | 7 | 2004 | 133 | 0.140 |
Why?
| | Myocardium | 8 | 2004 | 913 | 0.140 |
Why?
| | Disease Models, Animal | 8 | 2013 | 3535 | 0.130 |
Why?
| | Systole | 4 | 2001 | 171 | 0.130 |
Why?
| | Heart Function Tests | 2 | 2013 | 58 | 0.120 |
Why?
| | Metformin | 1 | 2017 | 276 | 0.110 |
Why?
| | Dobutamine | 3 | 2000 | 33 | 0.110 |
Why?
| | Insulin Resistance | 2 | 2013 | 1072 | 0.110 |
Why?
| | Actinin | 1 | 2012 | 13 | 0.100 |
Why?
| | Hypertension | 1 | 2000 | 1056 | 0.100 |
Why?
| | Nitric Oxide Synthase Type III | 2 | 2013 | 184 | 0.100 |
Why?
| | Diastole | 3 | 2001 | 130 | 0.100 |
Why?
| | Uncertainty | 1 | 2012 | 95 | 0.100 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 318 | 0.100 |
Why?
| | Dietary Fats | 2 | 2013 | 287 | 0.100 |
Why?
| | Central Venous Pressure | 1 | 2011 | 12 | 0.090 |
Why?
| | Radionuclide Imaging | 1 | 2011 | 115 | 0.090 |
Why?
| | Reperfusion Injury | 2 | 2005 | 255 | 0.090 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 347 | 0.080 |
Why?
| | Obesity | 2 | 2013 | 2508 | 0.080 |
Why?
| | Ischemia | 1 | 2012 | 362 | 0.080 |
Why?
| | Premedication | 1 | 2008 | 36 | 0.080 |
Why?
| | Hyperhomocysteinemia | 1 | 2008 | 24 | 0.080 |
Why?
| | Radiography | 1 | 2011 | 812 | 0.080 |
Why?
| | Insulin | 3 | 2013 | 2082 | 0.080 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2008 | 157 | 0.080 |
Why?
| | Hypoglycemic Agents | 3 | 2012 | 1012 | 0.080 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2008 | 161 | 0.080 |
Why?
| | KATP Channels | 1 | 2008 | 16 | 0.070 |
Why?
| | Densitometry | 1 | 2007 | 29 | 0.070 |
Why?
| | Spectrin | 1 | 2007 | 13 | 0.070 |
Why?
| | Ultrasonography | 1 | 2011 | 634 | 0.070 |
Why?
| | Desmin | 1 | 2007 | 31 | 0.070 |
Why?
| | Rats, Wistar | 1 | 2008 | 368 | 0.070 |
Why?
| | Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2007 | 37 | 0.070 |
Why?
| | Purines | 1 | 2008 | 159 | 0.070 |
Why?
| | Troponin | 1 | 2007 | 44 | 0.070 |
Why?
| | Heart-Assist Devices | 1 | 2012 | 485 | 0.070 |
Why?
| | Calcium-Binding Proteins | 1 | 2007 | 206 | 0.070 |
Why?
| | Phosphocreatine | 3 | 1994 | 36 | 0.060 |
Why?
| | Fenofibrate | 1 | 2005 | 24 | 0.060 |
Why?
| | Fetus | 1 | 2010 | 700 | 0.060 |
Why?
| | Protein Processing, Post-Translational | 1 | 2007 | 399 | 0.060 |
Why?
| | Oxygen Consumption | 4 | 1996 | 588 | 0.060 |
Why?
| | Blood Pressure | 4 | 2009 | 1538 | 0.060 |
Why?
| | Female | 15 | 2017 | 59571 | 0.060 |
Why?
| | Ventricular Function, Left | 4 | 2004 | 467 | 0.060 |
Why?
| | Nitric Oxide | 1 | 2008 | 823 | 0.050 |
Why?
| | Phosphorylation | 3 | 2013 | 1569 | 0.050 |
Why?
| | Prognosis | 1 | 2011 | 3330 | 0.050 |
Why?
| | Glucose | 3 | 2013 | 897 | 0.050 |
Why?
| | Humans | 6 | 2012 | 114709 | 0.050 |
Why?
| | Oxidative Stress | 1 | 2008 | 1076 | 0.050 |
Why?
| | Endothelium, Vascular | 1 | 2008 | 847 | 0.050 |
Why?
| | Myocardial Infarction | 1 | 2008 | 927 | 0.050 |
Why?
| | Fatty Acids, Nonesterified | 3 | 2004 | 151 | 0.050 |
Why?
| | Insulin Receptor Substrate Proteins | 2 | 2013 | 56 | 0.050 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2003 | 192 | 0.050 |
Why?
| | Diacetyl | 1 | 2001 | 7 | 0.050 |
Why?
| | Apoptosis | 1 | 2010 | 2363 | 0.050 |
Why?
| | Cytokines | 2 | 2005 | 1841 | 0.050 |
Why?
| | Cardiovascular Diseases | 1 | 2012 | 1728 | 0.050 |
Why?
| | Rats | 1 | 2008 | 4959 | 0.040 |
Why?
| | Hexamethonium | 1 | 2000 | 3 | 0.040 |
Why?
| | Atropine | 1 | 2000 | 25 | 0.040 |
Why?
| | Dilatation, Pathologic | 1 | 2000 | 55 | 0.040 |
Why?
| | Pericardium | 1 | 2000 | 50 | 0.040 |
Why?
| | Potassium | 1 | 2000 | 128 | 0.040 |
Why?
| | Infant, Newborn | 1 | 2010 | 5048 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 2 | 2013 | 398 | 0.040 |
Why?
| | Cardiovascular Agents | 1 | 2000 | 126 | 0.040 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 1995 | 473 | 0.040 |
Why?
| | Linear Models | 1 | 2000 | 768 | 0.040 |
Why?
| | Male | 7 | 2017 | 55667 | 0.040 |
Why?
| | Citrate (si)-Synthase | 1 | 2017 | 46 | 0.040 |
Why?
| | Signal Transduction | 1 | 2009 | 4517 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2017 | 124 | 0.030 |
Why?
| | Cardiac Catheterization | 1 | 2000 | 534 | 0.030 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2017 | 172 | 0.030 |
Why?
| | Diet | 2 | 2013 | 1080 | 0.030 |
Why?
| | Transcription Factors | 1 | 2003 | 1528 | 0.030 |
Why?
| | Phosphorus | 1 | 1995 | 82 | 0.030 |
Why?
| | Stroke Volume | 1 | 1997 | 504 | 0.030 |
Why?
| | Pulmonary Artery | 1 | 2000 | 1016 | 0.030 |
Why?
| | Electric Stimulation | 1 | 1995 | 250 | 0.030 |
Why?
| | Chromans | 2 | 2004 | 21 | 0.030 |
Why?
| | Acyl Coenzyme A | 1 | 2013 | 30 | 0.030 |
Why?
| | Hydroxy Acids | 1 | 2012 | 3 | 0.030 |
Why?
| | Decanoic Acids | 1 | 2012 | 7 | 0.030 |
Why?
| | Ischemic Preconditioning, Myocardial | 1 | 2012 | 29 | 0.030 |
Why?
| | Cardiolipins | 1 | 2013 | 71 | 0.030 |
Why?
| | Potassium Channel Blockers | 1 | 2012 | 29 | 0.030 |
Why?
| | Blood Glucose | 2 | 2013 | 1828 | 0.030 |
Why?
| | Glyburide | 1 | 2012 | 35 | 0.020 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2012 | 106 | 0.020 |
Why?
| | Biopsy | 1 | 1995 | 1036 | 0.020 |
Why?
| | Arteries | 1 | 2013 | 247 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2013 | 276 | 0.020 |
Why?
| | Cholesterol | 1 | 2013 | 367 | 0.020 |
Why?
| | Death, Sudden, Cardiac | 1 | 2012 | 160 | 0.020 |
Why?
| | Coronary Vessels | 1 | 2012 | 227 | 0.020 |
Why?
| | Vasodilation | 1 | 2013 | 419 | 0.020 |
Why?
| | Adult | 1 | 2010 | 30561 | 0.020 |
Why?
| | Adiponectin | 1 | 2009 | 213 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2009 | 329 | 0.020 |
Why?
| | Time Factors | 1 | 1997 | 6114 | 0.020 |
Why?
| | RNA, Messenger | 2 | 2004 | 2553 | 0.020 |
Why?
| | PPAR alpha | 1 | 2005 | 52 | 0.020 |
Why?
| | Heart Rate | 2 | 2001 | 709 | 0.020 |
Why?
| | Hypolipidemic Agents | 1 | 2005 | 86 | 0.020 |
Why?
| | Sus scrofa | 1 | 2004 | 45 | 0.010 |
Why?
| | alpha-Tocopherol | 1 | 2004 | 25 | 0.010 |
Why?
| | Isoproterenol | 2 | 1994 | 106 | 0.010 |
Why?
| | Thiazoles | 1 | 2003 | 110 | 0.010 |
Why?
| | Verapamil | 1 | 2001 | 32 | 0.010 |
Why?
| | Organ Preservation Solutions | 1 | 2001 | 39 | 0.010 |
Why?
| | Antioxidants | 1 | 2004 | 530 | 0.010 |
Why?
| | Arrhythmias, Cardiac | 1 | 2003 | 279 | 0.010 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2003 | 358 | 0.010 |
Why?
| | Drug Combinations | 1 | 2000 | 287 | 0.010 |
Why?
| | Microscopy, Electron | 1 | 1999 | 410 | 0.010 |
Why?
| | Elasticity | 1 | 1999 | 189 | 0.010 |
Why?
| | Blood Flow Velocity | 1 | 1999 | 387 | 0.010 |
Why?
| | Lactic Acid | 1 | 1996 | 275 | 0.010 |
Why?
| | Regional Blood Flow | 1 | 1996 | 424 | 0.010 |
Why?
| | Fat Emulsions, Intravenous | 1 | 1994 | 27 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 1994 | 173 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2003 | 2320 | 0.010 |
Why?
| | Lactates | 1 | 1994 | 79 | 0.010 |
Why?
| | Mitochondria, Heart | 1 | 1994 | 73 | 0.010 |
Why?
| | NAD | 1 | 1994 | 63 | 0.010 |
Why?
| | Glycine | 1 | 1994 | 152 | 0.010 |
Why?
| | Oxidative Phosphorylation | 1 | 1994 | 155 | 0.010 |
Why?
| | Heparin | 1 | 1994 | 224 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2005 | 9089 | 0.010 |
Why?
| | Cardiac Output, Low | 1 | 1992 | 64 | 0.010 |
Why?
|
|
Greyson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|